| Chemotherapy of acute myeloblastic leukaemia with DAM regimen. | |
| | |
MedLine Citation:
|
PMID: 9621477 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
32 patients of denovo-ANLL were treated with Doxorubicin, Ara-C and 6-Mercaptopurine (DAM) regimen. Remission induction was instituted with 1-3 cycles of DAM regimen and maintenance was given by 6-MP continuously with intermittent DA (1,5) regimen. In the remission induction, Doxorubicin 30 mg/m2 for 3 days, Ara-C 150 mg/m2 for 5 days and 6-Mp 100 mg/m2 daily was given. Complete remission (CR) was observed in 60% cases. The probability of 2 years disease-free survival of patients with complete remission is 56.73%. |
| | |
Authors:
|
A B Yunus; M A Sayeed; A Barua; J Rahman; M A Rashid |
Related Documents
:
|
9864917 - Disappearance of pml/rar alpha acute promyelocytic leukemia-associated transcript durin... 20029047 - Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute p... 284167 - Adriamycin in combination chemotherapy of adult acute lymphoblastic leukemia: a southwe... 15291357 - Molecular disease eradication is a prerequisite for long-term remission in patients wit... 11780387 - Treatment of hepatic failure with artificial liver support system. 17690257 - Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Bangladesh Medical Research Council bulletin Volume: 23 ISSN: 0377-9238 ISO Abbreviation: Bangladesh Med Res Counc Bull Publication Date: 1997 Dec |
Date Detail:
|
Created Date: 1998-07-08 Completed Date: 1998-07-08 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7607686 Medline TA: Bangladesh Med Res Counc Bull Country: BANGLADESH |
Other Details:
|
Languages: eng Pagination: 82-6 Citation Subset: IM |
Affiliation:
|
Department of Haematology, Institute of Postgraduate Medicine & Research, Dhaka. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use* Blood Cell Count / drug effects Cytarabine / administration & dosage Disease-Free Survival Doxorubicin / administration & dosage Drug Administration Schedule Female Humans Leukemia, Myeloid, Acute / drug therapy* Male Middle Aged Remission Induction |
| Chemical | |
Reg. No./Substance:
|
0/AA1-3 protocol; 147-94-4/Cytarabine; 23214-92-8/Doxorubicin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Immunofluorescent microscopic findings in glomerulonephritis.
Next Document: Cut throat injury: a retrospective study of 26 cases.